No abstract available
MeSH terms
-
Antibodies, Monoclonal / administration & dosage
-
CTLA-4 Antigen / immunology
-
Clinical Trials, Phase III as Topic
-
Genes, cdc / drug effects
-
Genes, cdc / immunology
-
Humans
-
Immunotherapy / methods*
-
Immunotherapy / trends
-
Ipilimumab
-
Melanoma / immunology
-
Melanoma / pathology
-
Melanoma / therapy*
-
Neoplasm Metastasis
-
Nivolumab
-
Programmed Cell Death 1 Receptor / immunology
Substances
-
Antibodies, Monoclonal
-
CTLA-4 Antigen
-
Ipilimumab
-
PDCD1 protein, human
-
Programmed Cell Death 1 Receptor
-
Nivolumab